Boston, MA -- (SBWIRE) -- 09/11/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Janus Capital Group Inc(NYSE:JNS), The Ryland Group, Inc. (NYSE:RYL), Exelixis, Inc. (NASDAQ:EXEL), Northstar Realty Finance Corp. (NYSE:NRF)
Janus Capital Group Inc(NYSE:JNS) shares gained 1.16% to $8.69. The company, on July 25 reported second quarter net income of $15.8 million, or $0.08 per diluted share, compared with first quarter 2013 net income of $28.0 million, or $0.15 per diluted share, and net income of $23.4 million, or $0.13 per diluted share, in the second quarter 2012.
Second quarter 2013 included a charge of $0.04 per share from the early extinguishment of debt associated with the exchange of $110.0 million of JCG's 3.25% convertible senior notes due 2014 for $116.6 million of newly issued 0.75% convertible senior notes due 2018 and a charge of $0.02 per share (or a $0.04 per share decline quarter over quarter) primarily due to the mark-to-market impact on our seed capital program.
How Should Investors Trade JNS After The Recent Volatility? Get Free Report Here
The Ryland Group, Inc. (NYSE:RYL) shares declined 0.61% to $37.54. Research analysts at Credit Suisse lowered their price target on shares of Ryland Group from $46.00 to $44.00 in a report released on Sept. 10. The firm currently has a “neutral” rating on the stock.
Additionally, the company announced its earnings results on July 24. The company reported $0.80 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.64 by $0.16. The company had revenue of $492.99 million for the quarter, compared to the consensus estimate of $492.80 million.
How Should Investors Trade RYL After The Recent Volatility? Get Free Report Here
Exelixis, Inc. (NASDAQ:EXEL) shares increased 1.73% to $5.59. The company on Sept. 10 announced that it has initiated CELESTIAL, a phase 3 pivotal trial comparing cabozantinib with placebo in patients with advanced hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The primary endpoint for the trial is overall survival (OS). CELESTIAL is a randomized, double blind, placebo controlled study of cabozantinib in patients with advanced HCC that is being conducted at up to 200 sites globally in up to 30 countries.
Is EXEL A Good Buy After The Recent Price Movement? Find Out Here
Northstar Realty Finance Corp. (NYSE:NRF) shares closed at $8.93. The company, on August 16, announced that NorthStar Real Estate Income Trust, Inc., its first sponsored non-traded REIT, successfully priced a $531.5 million non-recourse, floating-rate CMBS transaction at a weighted average coupon of LIBOR + 2.68%. The CMBS transaction will initially be collateralized by $425.2 million of commercial real estate loans with the flexibility to contribute up to $106.3 million of additional commercial real estate loans within six months of closing.
Is NRF A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)